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Summary: Blood samples from 104 patients with clinically suspected thrombophilia were analyzed for coagulation
factor V Leiden mutation (1691, G—»A) by allele-specific polymerase chain reaction. In 86 individuals (82.7%),
the mutation was not detectable, whereas 15 patients (14.4%) were heterozygous and three patients (2.9%) were
homozygous for factor V Leiden mutation. Plasma samples from these individuals were also tested for functional
resistance of coagulation factor V to activated protein C (activated protein C resistance). This test was performed
on a Schnitger-Gross coagulometer using an activated partial thromboplastin time-based activated protein C resis-
tance test modified by applying a 1 : 5 dilution with factor V-deficiency plasma. All the individuals negative for
factor V Leiden mutation were also negative in the functional activated protein C resistance test. On the other hand,
all patients carrying the mutation revealed pathologic results in the activated protein C resistance test. The cutoff
value for the activated protein C resistance index (> 1.7 = negative) was determined by testing 31 male and female
blood donors. One of them was heterozygous for factor V Leiden mutation and had an activated protein C resistance
index of 1.4, whereas those without factor V Leiden mutation had an activated protein C resistance index of
1.9 ± 0.1 (χ ± SD). Patients with clinically suspected thrombophilia without factor V Leiden mutation had an
activated protein C resistance index of 2.1 ± 0.2 (x ± SD), whereas patients heterozygous for the mutation had an
index of 1.5 ± 0.1 (x ± SD). Within the group of patients carrying the mutation, the activated protein C resistance
test even distinguished between heterozygous and three homozygous (activated protein C resistance 1.0 to 1.2)
carriers. The data demonstrate that the activated protein C resistance test in the presence of factor V-deficiency
plasma provides a clear-cut discrimination between normal wildtype and carriers of factor V Leiden mutation with
a sensitivity and specificity of 100%. Verification of positive activated protein C resistance tests can be performed
easily with a simple and reliable polymerase chain reaction protocol for the 1691, G—»A mutation.
Introduction
Resistance of coagulation factor V to activated protein factor V (factor Va) by activated protein C. It is assumed
C is reported to be the most prevalent coagulation abnor- that at least 90% of cases of functional activated protein
mality associated with venous thrombosis and embo- C resistance are caused by the factor V Leiden mutation
lism. Activated protein C resistance is more prevalent (1). Heterozygosity for the gene defect is associated with
than all other known coagulation abnormalities associ- a 5-to 10-fold higher risk of thrombosis, whereas homo-
ated with venous thrombosis together. It occurs in at zygosity for the mutation seems to be associated with a
least 20% of patients with a history of thromboembo- 50- to 100-fold increased risk. The risk is further en-
lism, as well as in the asymptomatic general European hanced by other coagulation abnormalities such as defi-
population, at a prevalence of up to ten percent (1-4). ciency of antithrombin III, protein C or protein S (1,
As described by Bertina et al. (4), the phenotype of acti- 5~8)· Because of cost-to-risk estimations, genotypic
vated protein C resistance is associated with a single screening for factor V Leiden in women taking oral con-
point mutation in the coagulation factor V gene at nucle- traceptives has been suggested (9-11).
otide position 1691 (guanine (G) to adenine (A) substi- Molecular biology based diagnosis of factor V Leiden
tution; 1691, G—»A), resulting in the synthesis of a mutation can be achieved by polymerase chain reaction
factor V molecule with the substitution of glutamine (Q) analysis, for which many protocols have been described,
for arginine (R) at amino acid residue number 506, Determination of activated protein C resistance might be
named factor V Q506 or factor V Leiden (4). The conse- used as well, since the mutation results in functional
quence of the mutation is loss of an activated protein C activated protein C resistance. However, it has been de-
cleavage site at amino acid residue 506, resulting in an monstrated that the conventional activated partial throm-
insufficient inactivation of membrane-bound activated boplastin time-based activated protein C resistance assay
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is influenced by deficiency of coagulation factors, anti-
coagulatory therapy, lupus anticoagulant and protein S
deficiency (12—14). As a consequence, the activated
protein C resistance test exhibits an unacceptably low
sensitivity and specificity for the detection of the muta-
tion. Thus, polymerase chain reaction techniques ap-
peared to be indispensable for screening of factor V
Leiden mutation in patients with suspected or mani-
fested thrombophilia, especially when patients are under
anticoagulatory therapy (13).
In order to avoid the influence of coagulation factor or
protein S deficiencies, anticoagulation etc. in functional
activated protein C resistance tests, some authors used
patients' samples upon dilution with factor V deficient
plasma (15, 16). This modification significantly im-
proved sensitivity and specificity of the activated protein
C resistance test. As a result, the modified activated pro-
tein C-resistance test has been proposed as a screening
method in diagnosis of factor V Leiden mutation (15-
19). On the other hand, it has been shown that the modi-
fied test does not clearly discriminate between normal
wildtype and homozygous or heterozygous carriers of
factor V Leiden mutation in each case (20). Other
groups still use the unmodified activated protein C-resis-
tance test with its low sensitivity and specificity for the
detection of factor V Leiden mutation (21, 22).
We used an activated partial thromboplastin time-based
activated protein C-resistance test modified by a 1 :5
dilution of plasma samples with factor V deficiency
plasma and performed it on a non-automatized
Schnitger-Gross coagulometer. It was demonstrated that
the modified activated protein C resistance test detects
factor V Leiden mutation with a sensitivity and specific-
ity of 100% and even discriminates heterozygous and
homozygous forms of the mutation. Verification of the
kind of mutation can be restricted to samples with posi-
tive activated protein C resistance tests and can be per-
formed easily with the allele-specific polymerase chain
reaction protocol used here.
Materials and Methods
Materials
The Chromogenix activated protein C resistance test kit (Coatest)
and factor V deficiency plasma were obtained from H mochrom
Diagnostika (Essen, Germany). Polymerase chain reaction primers
and dNTPs were purchased from Pharmacia (Freiburg, Germany).
Proteinase K was supplied by Sigma (Munich, Germany). Taq
polymerase was purchased from Gibco (Karlsruhe, Germany). All
other chemicals were analytical or molecular biological grade and
obtained from commercial sources.
Study population and blood sampling
Citrated plasma samples (venous blood : 0.1 mol/1 sodium citrate
= 10:1) were obtained from male and female patients with clini-
cally suspected thrombophilia referred to our laboratory, or from
male and female blood donors for determination of reference val-
ues. Platelet-poor plasma was obtained by two centrifugation steps
of 10 min each at 2000 g at room temperature. The plasma was
collected carefully, strictly avoiding contamination with platelets.
Aliquots were frozen at —25 °C.
Activated protein C resistance test
Plasma samples were thawed immediately before testing by incu-
bation at 37 °C for exactly 10 min. Each sample was prediluted
with factor V deficiency plasma (1 : 5) to exclude effects of other
factors than factor V Leiden mutation on the activated protein C
resistance test. Diluted plasma samples (100 μΐ) were mixed with
100 μΐ prewarmed activated partial thromboplastin time reagent
and incubated for 5 min at 37 °C. Coagulation on a Schnitger-
Gross coagulometer (Amelung, Lemgo, Germany) was started by
adding either 100 μΐ CaCl2 (0.025 mol/1) or a mixture of activated
protein C and CaCl2. The results were expressed as a ratio of the
coagulation time obtained with the CaCl2-activated protein C mix-
ture over CaCl2 without activated protein C (activated protein C
resistance index).
DNA preparation and identification of the
1691, G—»A mutat ion in the factor V gene
Genomic DNA was prepared from peripheral blood leukocytes by
a standard procedure. In brief, cells were lysed by mixing 100 μΐ
EDTA-blood samples with 500 μΐ Tris/EDTA buffer (10 mmol/1
Tris-HCl, pH 8.0 and 1 mmol/1 EDTA). The nuclei were pelleted
by centrifugation for 10 s at 13 000 g. Supernatants were decanted
and the procedure was repeated one to two times until clean nuclei
pellets were obtained. The pellets were resuspended in 100 μΐ lysis
buffer containing 10 mmol/1 Tris-HCl, pH 8.3, 50 mmol/1 KC1, 1.5
mmol/1 MgCl2, 0.1 g/1 gelatin and 5 g/1 Tween 20. After adding
10 μΐ proteinase Κ (10 g/1), the samples were incubated for 45 min
at 56 °C followed by incubation for 10 min at 95 °C to inactivate
proteinase K. DNA samples were stored at —25 °C.
Allele-specific polymerase chain reaction was performed using
primers recently described (2, 23): Factor V FOR2 (5* consensus
primer): 5' AGGAACAACAACATGATC 3'; Factor V NOR: 5'
GGACAAAATACCTGTATTCCAC 3'; Factor V MUT: 5' GGA-
CAAAATACCTGTATTCCAT 3'. Duplicate samples of genomic
DNA from each individual were subjected to polymerase chain
reaction with either the Factor V FOR2/Factor V NOR primer set
specific for the "G" (normal) allele or the Factor V FOR2/Factor
V MUT primer set specific for the "A" (mutant) allele. The speci-
ficity of the allele-specific primers was extremely high by incorpo-
ration of an additional mismatch at the penultimate position (23).
Polymerase chain reaction conditions were: 20 mmol/1 Tris-HCl,
pH 8.4, 50 mmol/1 KC1, 0.01 g/1 gelatin, 0.5 g/1 Tween 20, 1.5
mmol/1 MgCl2, 0.2 mmol/1 of each dNTP, 0.5 μιηοΐ/ΐ of each factor
V related primer, 0.5 U Taq polymerase, and approx. 100 ng geno-
mic DNA in a final reaction volume of 25 μΐ. The samples were
overlaid with 25 μΐ mineral oil and thermocycling was performed
using the thermocycler TR1 from MWG-Biotech (Ebersberg, Ger-
many) with the following protocol: 1) 94 °C, 2 min (hotstart dena-
turation); 57 °C, 30 s (annealing); 72 °C, 30 s (extention) for one
cycle and 2) 94 °C, 15 s; 57 °C, 15 s; 72 °C, 30 s for the following
29 cycles. Products (224 base pairs) were separated by 2% agarose
gel electrophoresis and visualized by ethidium bromide staining.
Each DNA sample was analyzed twice.
Results
Reference values for the modified activated
protein C resistance test
Determination of reference values for the activated pro-
tein C resistance index was performed by testing 31
blood donors between the ages of 20 to 64 years, ap-
proximately corresponding to the ages of patients in the
study. The 30 individuals without factor V Leiden muta-
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tion had indices between 1.7 and 2.1 (fig. 2a). The mean
value (x) of the activated protein C resistance index was
1.9, the standard deviation (SD) was 0.1. The cutoff
value determined as χ — 2 SD was 1.7. None of the
blood donors without factor V Leiden mutation had an
activated protein C resistance index lower than 1.7. One
blood donor had an index of 1.4 and the genotype was
heterozygous for the mutation.
Comparison of the genotype test for factor V
Leiden mutation with the modified functional
test for activated protein C resistance
Blood samples from 104 patients with clinically sus-
pected thrombophilia were tested for factor V Leiden
mutation by allele-specific polymerase chain reaction.
Definite signals were obtained in the DNA of homozy-
gous normal patients as well as in patients heterozygous
or homozygous for factor V Leiden (fig. 1). Eighty-six
individuals (82.7%) were normal, 15 (14.4%) were het-
erozygous and three individuals (2.9%) were homozy-
gous for factor V Leiden (fig. 2b). Selecting the patients
by the criterium "clinically manifested thrombosis",
factor V Leiden mutation was detected in 32% of the in-
dividuals.
Using the modified activated protein C resistance test as
described in Materials and Methods and the cutoff value
of the activated protein C resistance index of 1.7, all
patients without factor V Leiden were detected as nor-
mal in an index range between 1.7 and 2.5 with a mean
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Fig. 1 Agarose gel electrophoresis of amplification products ob-
tained by allele-specific polymerase chain reaction of factor V
Leiden mutation.
Polymerase chain reaction was performed using specific pairs of
primers for amplification of either the normal (wildtype) allele or
of the mutant allele of factor V. Amplification products (224 base
pairs) we stained by ethidium bromide. Tracks are as follows:
1 and 10: 100 base pairs ladder; 2 and 3: wildtype and mutation
amplification of an individual without factor V Leiden mutation; 4
and 5: wildtype and mutation amplification of a heterozygous pa-
tient; 6 and 7: wildtype and mutation amplification of a homozy-
gous carrier of factor Leiden mutation; 8 and 9: wildtype and muta-
tion amplification of reagent controls without genomic DNA.
Markers indicate the position of the specific 224 base pair amplifi-
cation products. One of two identical polymerase chain reaction
assays is shown.
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Fig. 2 Activated protein C resistance indices of blood donors and
of patients with clinically suspected thrombophilia.
Activated protein C resistance indices of blood donors (a) and of
patients with suspected thrombophilia (b) were determined as out-
lined in Materials and Methods. Molecular biology-based classifi-
cation of individuals was performed as described in figure 1. Cutoff
values were 1.7 for heterozygous and 1.3 for homozygous carriers
of factor V Leiden mutation.
value of 2.1 (SD = 0.2). Patients heterozygous for factor
V Leiden had indices between 1.3 and 1.6 with a mean
value of 1.5 (SD = 0.1), whereas the three patients
found homozygous for the mutation had activated pro-
tein C resistance indices of 1.0 and 1.2 (fig. 2b). One of
these patients with an index of 1.2 suffered from acute
lung embolism and therefore was under therapy with
heparin when citrated blood samples were taken for the
activated protein C resistance test.
Discussion
Venous thrombosis occurs with a prevalence of 1/1000
individuals. The major reason for genetically determined
thrombosis is resistance of coagulation factor V to acti-
vated protein C (activated protein C resistance), which
is found in 20—60% of patients with venous thrombosis
(1). At least 90% of cases of functional activated protein
C resistance are caused by a single point mutation in the
factor V gene named factor V Leiden (1, 4). We found
activated protein C resistance/factor V Leiden in 17%
of patients with suspected thrombophilia and in 32% of
those with clinically manifested thromboembolic events.
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This is in line with the frequencies of factor V Leiden
mutation reported by others (1-4). Patients homozy-
gous for factor V Leiden mutation have also been shown
to have a higher recurrence rate for thrombosis as com-
pared with a control population (24). Thus, it seems to
be indispensable for medical laboratories to offer tests
for screening and verification of activated protein C re-
sistance/factor V Leiden.
A definite method for detecting the mutation is the poly-
merase chain reaction. However, some protocols pub-
lished so far are troublesome and can lead to equivocal
results. On the other hand, testing of activated protein C
resistance lacks specificity and sensitivity when using
the conventional assay (14, 21, 22). Whether the acti-
vated protein C resistance test in samples diluted with
factor V deficient plasma provides clear-cut discrimina-
tion between normal wildtype and carriers of factor V
Leiden mutation is still matter of debate (15-20).
We adapted the activated partial thromboplastin time-
based activated protein C resistance test with factor V
deficient plasma dilution to a Schnitger-Gross coagulo-
meter and were able to detect factor V Leiden mutation
with a sensitivity and specificity of 100% in 104 patients
and 31 blood donors. This is consistent with recent re-
ports showing similar results from studies performed on
fully automated coagulation systems that are not avail-
able in each medical laboratory (17, 18). In these studies
the cutoff values for activated protein C resistance in-
dices were between 2 and 2.5, whereas we found a cut-
off value of 1.7 (determined by testing blood donors
without the mutation) clearly discriminating patients
without the mutation from heterozygous patients. Thus,
it seems to be necessary that each laboratory determines
its reference values for the activated protein C resistance
index that refer to the analytical system and to the indi-
vidual protocol used. The fact that in other hands the
modified activated protein C resistance test did not
discriminate in each case (20) might depend on a lack
of exact assay standardization, as was also observed in
our hands when evaluating the test (not shown). There-
fore, it might be useful to verify positive or questionable
results of the activated protein C resistance test, espe-
cially in the phase of test evaluation. The allele-specific
polymerase chain reaction protocol described here
proved to be reliable and easy to perform.
In the present study, a cutoff value for the activated pro-
tein C resistance index of 1.3 discriminated heterozy-
gous from homozygous carriers of the mutation. How-
ever, the number of three individuals homozygous for
factor V Leiden mutation was too small to allow a fun-
damental statement. The mean value of the activated
protein C resistance index of blood donors without
factor V Leiden was 1.9, whereas the mean value in
patients without carrying the mutation was 2.1. The dif-
ference in mean values might be due to the fact that in
contrast to healthy blood donors, the hospitalized pa-
tients were suffering from various diseases and as a rule
were under drug treatment. Despite this, the cutoff deter-
mined by testing blood donors also strictly discriminated
patients with or without the mutation.
It has been reported that the activated protein C resis-
tance test with factor V deficient plasma is even valid in
patients with oral anticoagulation or parenteral heparin
therapy (15—17, 19, 25). This is in line with our obser-
vation that one patient with intravenous application of
heparin was detected accurately to be homozygous for
factor V Leiden by the modified activated protein C re-
sistance test.
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